STOCK TITAN
  1. Home
  2. News
  3. HNSA

HNSA - $HNSA STOCK NEWS

Welcome to our dedicated page for HNSA news (Ticker: $HNSA), a resource for investors and traders seeking the latest updates and insights on HNSA stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HNSA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HNSA's position in the market.

News
Hansa Biopharma publishes 2023 Annual and Sustainability Reports
Rhea-AI Summary
Hansa Biopharma AB made significant progress across commercial and R&D priorities in 2023, focusing on sustainability and innovation. The company expanded access in Europe, achieved positive clinical trial results, and advanced gene therapy collaborations. They also emphasized sustainability efforts and received recognition for workplace culture.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
Rhea-AI Summary
Hansa Biopharma appoints Evan Ballantyne as CFO, bringing over 30 years of international financial experience. His role includes developing financial strategies, reporting, and investor relations. The company aims to enhance shareholder value and advance its strategic priorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation
Rhea-AI Summary
Hansa Biopharma (Nasdaq Stockholm: HNSA) announced that imlifidase significantly reduced donor-specific antibodies (DSAs) by 94.4% within 5 days of treatment, compared to 35.6% reduction with standard of care, in the 16-HMedIdeS-12 phase 2 trial for patients with antibody mediated rejection (AMR) episodes following a kidney transplant. The trial also showed a 74% six-month graft survival and eGFR of 30mL/min/1.73m2 in the imlifidase arm, with a safety profile consistent with previous clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)
Rhea-AI Summary
Hansa Biopharma (HNSA) announces positive high-level data from the 15-HMedIdeS-09 phase 2 trial, demonstrating the safety and effectiveness of imlifidase in GBS patients. The trial showed rapid improvement in disease-related efficacy measures, with further analysis expected in 2024. Imlifidase has the potential to be a promising new option for halting the progression of GBS, a rare, acute, paralyzing, inflammatory disease of the peripheral nervous system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables
Rhea-AI Summary
Hansa Biopharma (NASDAQ Stockholm: HNSA) plans to restructure the organization to focus on key clinical development and commercial priorities, resulting in a 20-25% reduction in the workforce and approximately 75-85 million SEK in annual savings. The restructuring aims to optimize investment in growth opportunities and position the company for long-term success.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study
Rhea-AI Summary
Hansa Biopharma announces positive outcomes from a study on kidney transplant patients who received imlifidase treatment, showing sustained positive outcomes up to 5 years. Patient survival rate was 90% after 5 years, and graft survival was 82%. Mean estimated glomerular filtration rate (eGFR) at 5 years was 50 mL/min/m2. The results confirm the important role of imlifidase in desensitization in kidney transplantation. Imlifidase is conditionally approved in Europe as Idefirix® for the treatment of highly sensitized adult kidney transplant patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487
Rhea-AI Summary
Hansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma
Rhea-AI Summary
Hansa Biopharma appoints Dr. Hitto Kaufmann as Chief Scientific Officer (CSO) effective December 1, 2023. Dr. Kaufmann will be responsible for research, development, and manufacturing activities. He joins from Pieris Pharmaceuticals where he served as CSO and played a key role in the company's R&D platform. Hansa Biopharma is a mid-stage biotech company focused on rare immunologic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Hansa Biopharma: Increase of the number of votes
Rhea-AI Summary
Hansa Biopharma AB (Nasdaq Stockholm: HNSA) Announces Increase in Number of Votes and Shares, Delivering Ordinary Shares to Participants in Incentive Program
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Idefirix (imlifidase) receives provisional approval in Australia as desensitization treatment in highly sensitized patients prior to kidney transplantation
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock HNSA logo
HNSA

Nasdaq:HNSA

HNSA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

HNSA Stock Data